Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
AtriCure to hold an investor event » 13:45
09/28/22
09/28
13:45
09/28/22
13:45
ATRC

AtriCure

$39.57 /

+1.32 (+3.45%)

Investor Education Event…

Investor Education Event entitled, "Hybrid AF Therapy to be held on September 28 at 2 pm. Webcast Link

ShowHide Related Items >><<
ATRC AtriCure
$39.57 /

+1.32 (+3.45%)

ATRC AtriCure
$39.57 /

+1.32 (+3.45%)

08/03/22 Needham
AtriCure price target raised to $65 from $55 at Needham
08/03/22 Piper Sandler
AtriCure price target lowered to $55 from $90 at Piper Sandler
07/18/22 Stifel
AtriCure price target lowered to $50 from $70 at Stifel
07/05/22 Piper Sandler
Bottom in med tech shares is 'getting close,' says Piper Sandler
ATRC AtriCure
$39.57 /

+1.32 (+3.45%)

Conference/Events
AtriCure to hold an investor event » 11:19
09/28/22
09/28
11:19
09/28/22
11:19
ATRC

AtriCure

$38.96 /

+0.71 (+1.86%)

Investor Education Event…

Investor Education Event entitled, "Hybrid AF Therapy to be held on September 28 at 2 pm. Webcast Link

ShowHide Related Items >><<
ATRC AtriCure
$38.96 /

+0.71 (+1.86%)

ATRC AtriCure
$38.96 /

+0.71 (+1.86%)

08/03/22 Needham
AtriCure price target raised to $65 from $55 at Needham
08/03/22 Piper Sandler
AtriCure price target lowered to $55 from $90 at Piper Sandler
07/18/22 Stifel
AtriCure price target lowered to $50 from $70 at Stifel
07/05/22 Piper Sandler
Bottom in med tech shares is 'getting close,' says Piper Sandler
ATRC AtriCure
$38.96 /

+0.71 (+1.86%)

Tuesday
Recommendations
Artivion shares should be purchased on weakness, says Lake Street » 08:44
09/27/22
09/27
08:44
09/27/22
08:44
AORT

Artivion

$13.71 /

+0.39 (+2.93%)

Lake Street analyst Frank…

Lake Street analyst Frank Takkinen lowered the firm's price target on Artivion to $28 from $32 and keeps a Buy rating on the shares after the company announced last week that the Data and Safety Monitoring Board recommended halting the PROACT Xa trial was evaluating non-inferiority of apixaban as an anticoagulant in place of warfarin. While this news is "disappointing" given that it tightens the total addressable market, it "is not at all detrimental to the long-term thesis," argues Takkinnen. He thinks shares should be purchased on weakness given that this was one of six PMAs in the works, there is no PROACT Xa revenue contribution included in estimates through 2025 and stopping the trial frees up $10M of operating expenses that can be reallocated.

ShowHide Related Items >><<
AORT Artivion
$13.71 /

+0.39 (+2.93%)

AORT Artivion
$13.71 /

+0.39 (+2.93%)

09/26/22 Oppenheimer
Artivion price target lowered to $25 from $35 at Oppenheimer
09/07/22 Lake Street
Lake Street sees Artivion as $60 per share stock over long-term
08/08/22 Lake Street
Artivion initiated with a Buy at Lake Street
03/02/22 Stifel
Stifel starts 'transformed' Artivion at Buy with $30 price target
AORT Artivion
$13.71 /

+0.39 (+2.93%)

AORT Artivion
$13.71 /

+0.39 (+2.93%)

Monday
Recommendations
Artivion price target lowered to $25 from $35 at Oppenheimer » 07:32
09/26/22
09/26
07:32
09/26/22
07:32
AORT

Artivion

$13.33 /

-5.18 (-27.98%)

Oppenheimer analyst Suraj…

Oppenheimer analyst Suraj Kalia lowered the firm's price target on Artivion to $25 from $35 and keeps an Outperform rating on the shares after the company announced the PROACT Xa trial was being stopped due to futility of reaching non-inferiority of apixaban to warfarin for valve thrombosis and thromboembolism. The DSMB recommendation was based on higher ischemic stroke rates in the apixaban arm versus warfarin. While double-digit topline growth for full year 2022 was affirmed, and the $10M/year PROACT-Xa spend will be repurposed to other opportunities, this news, "unfortunately," compounds the outlook somewhat, Kalia argues.

ShowHide Related Items >><<
AORT Artivion
$13.33 /

-5.18 (-27.98%)

AORT Artivion
$13.33 /

-5.18 (-27.98%)

09/07/22 Lake Street
Lake Street sees Artivion as $60 per share stock over long-term
08/08/22 Lake Street
Artivion initiated with a Buy at Lake Street
03/02/22 Stifel
Stifel starts 'transformed' Artivion at Buy with $30 price target
03/02/22 Stifel
Artivion initiated with a Buy at Stifel
AORT Artivion
$13.33 /

-5.18 (-27.98%)

AORT Artivion
$13.33 /

-5.18 (-27.98%)

Friday
Hot Stocks
Artivion falls -29.0% » 12:03
09/23/22
09/23
12:03
09/23/22
12:03
AORT

Artivion

$13.05 /

-5.46 (-29.50%)

Artivion is down -29.0%,…

Artivion is down -29.0%, or -$5.36 to $13.14.

ShowHide Related Items >><<
AORT Artivion
$13.05 /

-5.46 (-29.50%)

AORT Artivion
$13.05 /

-5.46 (-29.50%)

09/07/22 Lake Street
Lake Street sees Artivion as $60 per share stock over long-term
08/08/22 Lake Street
Artivion initiated with a Buy at Lake Street
03/02/22 Stifel
Stifel starts 'transformed' Artivion at Buy with $30 price target
03/02/22 Stifel
Artivion initiated with a Buy at Stifel
AORT Artivion
$13.05 /

-5.46 (-29.50%)

AORT Artivion
$13.05 /

-5.46 (-29.50%)

Hot Stocks
Artivion falls -22.2% » 10:01
09/23/22
09/23
10:01
09/23/22
10:01
AORT

Artivion

$14.00 /

-4.51 (-24.37%)

Artivion is down -22.2%,…

Artivion is down -22.2%, or -$4.10 to $14.40.

ShowHide Related Items >><<
AORT Artivion
$14.00 /

-4.51 (-24.37%)

AORT Artivion
$14.00 /

-4.51 (-24.37%)

09/07/22 Lake Street
Lake Street sees Artivion as $60 per share stock over long-term
08/08/22 Lake Street
Artivion initiated with a Buy at Lake Street
03/02/22 Stifel
Stifel starts 'transformed' Artivion at Buy with $30 price target
03/02/22 Stifel
Artivion initiated with a Buy at Stifel
AORT Artivion
$14.00 /

-4.51 (-24.37%)

AORT Artivion
$14.00 /

-4.51 (-24.37%)

Hot Stocks
Artivion falls -20.0% » 09:52
09/23/22
09/23
09:52
09/23/22
09:52
AORT

Artivion

$14.51 /

-4 (-21.61%)

Artivion is down -20.0%,…

Artivion is down -20.0%, or -$3.70 to $14.80.

ShowHide Related Items >><<
AORT Artivion
$14.51 /

-4 (-21.61%)

AORT Artivion
$14.51 /

-4 (-21.61%)

09/07/22 Lake Street
Lake Street sees Artivion as $60 per share stock over long-term
08/08/22 Lake Street
Artivion initiated with a Buy at Lake Street
03/02/22 Stifel
Stifel starts 'transformed' Artivion at Buy with $30 price target
03/02/22 Stifel
Artivion initiated with a Buy at Stifel
AORT Artivion
$14.51 /

-4 (-21.61%)

AORT Artivion
$14.51 /

-4 (-21.61%)

Hot Stocks
Artivion stops PROACT Xa clinical trial » 07:04
09/23/22
09/23
07:04
09/23/22
07:04
AORT

Artivion

$18.51 /

-0.91 (-4.69%)

Artivion announced that…

Artivion announced that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin. The decision was based on the recommendation of the independent Data and Safety Monitoring Board of the trial due to lack of evidence supporting non-inferiority of apixaban to warfarin for valve thrombosis and thromboembolism. The PROACT Xa trial randomized patients having an On-X aortic valve replacement to receive either warfarin or apixaban as their anticoagulant to prevent blood clots. The trial began enrolling in April 2020. The DSMB found that blood clots, resulting in stroke, occurred more frequently in patients receiving apixaban and that continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk. Physician investigators at the trial's sites are being notified to change patients who are in the apixaban arm of the trial back to warfarin. CEO Pat Mackin said, "We are disappointed to stop the PROACT Xa trial as a successful trial would have significantly benefited patients and significantly increased our addressable market opportunity beginning in 2025. Despite stopping the trial, we are reiterating our 2022 outlook of delivering double-digit top-line growth and we remain committed to delivering the financial expectations we communicated in our March investor meeting: Double digit top-line growth, expanding gross margins, and accelerated adjusted EBITDA growth through 2024. We had committed approximately $10 million in annual funding to this study through 2024 and will now redirect these funds to other development opportunities and to incremental EBITDA and cash flow in 2023 and 2024."

ShowHide Related Items >><<
AORT Artivion
$18.51 /

-0.91 (-4.69%)

AORT Artivion
$18.51 /

-0.91 (-4.69%)

09/07/22 Lake Street
Lake Street sees Artivion as $60 per share stock over long-term
08/08/22 Lake Street
Artivion initiated with a Buy at Lake Street
03/02/22 Stifel
Stifel starts 'transformed' Artivion at Buy with $30 price target
03/02/22 Stifel
Artivion initiated with a Buy at Stifel
AORT Artivion
$18.51 /

-0.91 (-4.69%)

AORT Artivion
$18.51 /

-0.91 (-4.69%)

Over a week ago
Initiation
Alphatec initiated with an Overweight at Morgan Stanley » 05:21
09/12/22
09/12
05:21
09/12/22
05:21
ATEC

Alphatec

$8.34 /

+0.365 (+4.58%)

Morgan Stanley analyst…

Morgan Stanley analyst Drew Ranieri initiated coverage of Alphatec with an Overweight rating and $13 price target. Alphatec's "premium above-peer growth should continue for the foreseeable future with meaningful spine market share gains ahead," Ranieri tells investors in a research note. He says the company has commercial and technological critical mass to drive further share gains with the opportunity for margin improvement.

ShowHide Related Items >><<
ATEC Alphatec
$8.34 /

+0.365 (+4.58%)

ATEC Alphatec
$8.34 /

+0.365 (+4.58%)

07/15/22 Lake Street
Lake Street cuts Alphatec price target to $9, but would buy on weakness
05/06/22 H.C. Wainwright
Alphatec price target raised to $20 from $19 at H.C. Wainwright
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
ATEC Alphatec
$8.34 /

+0.365 (+4.58%)

ATEC Alphatec
$8.34 /

+0.365 (+4.58%)

ATEC Alphatec
$8.34 /

+0.365 (+4.58%)

Hot Stocks
Cue Health appoints Tsay as Chief Medical Officer » 09:18
09/08/22
09/08
09:18
09/08/22
09:18
HLTH

Cue Health

$3.61 /

+0.27 (+8.08%)

, AAPL

Apple

$155.95 /

+1.37 (+0.89%)

Cue Health (HTLH)…

Cue Health (HTLH) announced that it has appointed David Tsay, MD, PhD, as its Chief Medical Officer. Dr. Tsay comes to Cue with more than 20 years of experience in clinical medicine, research, and health technology. Most recently, Dr. Tsay served at Apple (AAPL), where he led an Apple Health clinical team in developing new Health products.

ShowHide Related Items >><<
HLTH Cue Health
$3.61 /

+0.27 (+8.08%)

AAPL Apple
$155.95 /

+1.37 (+0.89%)

HLTH Cue Health
$3.61 /

+0.27 (+8.08%)

03/30/22 Cowen
Cue Health price target lowered to $10 from $15 at Cowen
10/19/21
Fly Intel: Top five analyst initiations
10/19/21 BTIG
Cue Health initiated with a Buy at BTIG
10/19/21 Cowen
Cue Health initiated with an Outperform at Cowen
AAPL Apple
$155.95 /

+1.37 (+0.89%)

09/08/22 B. Riley
B. Riley sees 'ample value' in Globalstar shares after Apple pact
09/08/22 Oppenheimer
Apple integrated approach to design has little competition, says Oppenheimer
09/08/22 Deutsche Bank
Apple event does not change thesis on shares, says Deutsche Bank
09/08/22 Wedbush
iPhone 14 to kick off another strong product cycle despite macro, says Wedbush
HLTH Cue Health
$3.61 /

+0.27 (+8.08%)

AAPL Apple
$155.95 /

+1.37 (+0.89%)

  • 24
    Sep
HLTH Cue Health
$3.61 /

+0.27 (+8.08%)

AAPL Apple
$155.95 /

+1.37 (+0.89%)

HLTH Cue Health
$3.61 /

+0.27 (+8.08%)

AAPL Apple
$155.95 /

+1.37 (+0.89%)

HLTH Cue Health
$3.61 /

+0.27 (+8.08%)

AAPL Apple
$155.95 /

+1.37 (+0.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.